The new generation of thymidylate synthase inhibitors in clinical study

Expert Opinion on Investigational Drugs

Volumn 5, Issue 6, 1996, Pages 719-736

  Jackman, Ann L ^a   Judson, Ian R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000978627     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.5.6.719     Document Type: Review

References (123)

1. FRIEDKIN M, KORNBERG A: The enzymatic conversion of deoxyuridylic acid to thymidylic acid and the participation of tetrahydrofolic acid. In: The Chemical Basis of Heredity. McElroy WD, Glass B (Eds.), The John Hopkins Press, Baltimore (1957):609-614.
2. BORSAJ,WHITMOREGF:Cell killing studies on the mode of action of methotrexate on L cells in vitro. Cancer Res. (1969) 29:737-744.
3. TATTERSALL MHN, JACKSON RC, JACKSON STM, HARRAP KR: Factors determining cell sensitivity to methotrexate. Studies of folate and deoxyribonucleoslde triphosphate pools in five mammalfan cell lines. Eur. J. Cancer (1974) 10:819-826.
4. HARRAP KR, TAYLOR GA, BROWMAN GP: Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines. Chem. Biol. Interactions (1977) 18:119-128. (Pubitemid 8134402)
5. JACKSON RC, HARRAP KR: Studies with a mathematical model for folate metabolism. Arch. Biochem. Biophys. (1973) 158:119-128.
6. ULLMAN B, LEE M, MARTIN Jr DW, SANTI DV: Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc. Natl. Acad. Sci. USA (1978) 75:980-983. (Pubitemid 8298496)
7. MYERS CE: The pharmacology of the fluoropyrimidlne. Pharm. Revs. (1981) 33:1-15.
8. GREM JL: Fluorinated pyrimidines. In: Cancer Chemotherapy: Principles and Practice. Chabner BA, Collins JM (Eds.), JB Lippincott Co., Philadelphia (1990): 180-224.
9. PETERS GJ: Antimetabolites. In: The Scientific Basis for Cancer Treatment. Oxford Textbook of Oncology. Peckham M, Pinedo H, Veronesi U (Eds.), Oxford University Press, Oxford (1995) 1:524-552.
10. MATHERLEY LH, SEITHER RL, GOLDMAN ID: The basis for antifolate cytotoxicity, selectivity and metabolic transformations. Effects on utilisation of endogenous and exogenous folate cofactors. In: Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents. Powis G (Ed.), Oxford, Pergamon Press Ltd., UK (1994):139-177.
11. JACKSON RC, GRINDLEY GB: The biochemical basis for methotrexate cytotoxicity. In: Folate Antagonists as Therapeutic Agents. Academic Press, Inc. (1984) 1:289-315.
12. JACKMAN AL, JONES TR, CALVERT AH: Thymidylate synthase inhibitors: experimental and clinical aspects. In: Experimental and Clinical Progress in Cancer Chemotherapy. Muggia FM (Ed.), Martinus Nijhoff, Boston (1985):155-210.
13. JACKMAN AL, BOYLE FT, HARRAP KR: Tomudex (ZD1694): From concept to care, a programme in ra-tional drug discovery. Inv. New. Drugs (1996). In Press.
14. BIRD OD, VAITKUS JW, CLARKE J: 2-amino-4-hydroxy-quinazolines as inhibitors of thymidylate synthetase. Mol. Pharmacol. (1970) 6:573-575.
15. CALVERT AH, JONES TR, DADY PJ, GRZELAKOWSKA-SZTABERT B, PAINE RM, TAYLOR GA, HARRAP KR: Quina-zoline antlfolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance. Eur. J. Cancer (1980) 16:713-722. (Pubitemid 10114213)
16. MCCUEN RW, SIROTNAK FM: Thymidylate synthetase from Diplococcus pnuemoniae. Properties and inhibition by folate analogues. Biochim. Biophys. Acta (1975) 384:369-380.
17. CARLIN SC, ROSENBERG RN, VAN DE VENTER L, FRIEDKIN M: Quinazoline ant (folates as inhibitors of growth, dihydrofolate reductase and thymidylate synthetase of mouse neuroblastoma cells in culture. Mol. Pharmacol. 10:194-203.
18. CALVERT AH, JONES TR, JACKMAN AL, BROWN SJ, HARRAP KR: An approach to the design of antimetabolites active against cells resistant to conventional agents illustrated by quinazoline antlfolates with NIO-substitutions. In: Advances in Tumour Prevention, Detection and Characterisation. Davis W, Harrap KR (Eds.), Excerpta Medica, Amsterdam & Oxford (1980) 5:272-283.
19. JONES TR, CALVERT AH, JACKMAN AL, BROWN SJ, JONES M, HARRAP KR: A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice. Eur. J. Cancer (1981) 17:11-19. (Pubitemid 11167247)
20. JACKSON RC, JACKMAN AL, CALVERT AH: Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, CB3717, on human fymphoblastiod cells. Biochem. Pharmacol. (1983) 32:3783-3790.
21. JACKMAN AL, CALVERT AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol. (1995) 6:871-881.
22. CLARKE, SJ, JACKMAN AL, JUDSON IR: The history of the development and clinical use of CB3717 and ICID1694. In: Proc. of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation. Rustum Y (Ed.), Plenum Press. Adv. Exp. Med. Biol. (1993) 339:277-287. (Pubitemid 24073372)
23. CALVERT AH, ALISON DL, HARLAND SJ, ROBINSON BA, JACKMAN AL, JONES TR, NEWELL DR, SIDDICK ZH, WILT-SHAW E, MCELWAIN TJ, SMITH IE, HARRAP KR: A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J. Clin. Oncol. (1986) 4:1245-1252. (Pubitemid 16043876)
24. NEWELL DR, ALISON DL, CALVERT AH, HARRAP KR, JAR-MAN M, JONES TR, MANTEUFFEL-CYMBOROWSKA M, O'CONNOR P: Pharmacokinetics of the thymidylate synthase Inhibitor N10-propargyl-5,8-dideazfolic add (CB3717) in the mouse. Cancer Treat. Rep. (1986) 70:971-979. (Pubitemid 16041857)
25. ALISON DL, NEWELL DR, SESSA C, HARLAND SJ, HART LI, HARRAP, KR, CALVERT AH: The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8- dfcleazafo-lic acid (CB3717). Cancer Chemother. Pharmacol. (1985) 14:265-271. (Pubitemid 15118653)
26. CALVERT AH, NEWELL DR, JACKMAN AL, GUMBRELL LA, SKORA E, GZELAKOWSKASZTABERT B, BISHOP J, JUDSON IR, HARLAND SJ, HARRAP KR: Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10propargyl-5,8-dideazafolicacid(CB 3717). NO Monograph (1987) 5:213-218. (Pubitemid 18000424)
27. JACKMAN, AL, KIMBELL R, BROWN M, BRUNTON L, BISSET GMF, BAVETSIAS V, MARSHAM P, HUGHES LR, BOYLE FT: Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and poly-glutamation. Anticancer Drug Design (1995) 10:573-589.
28. DUCH DS, BANKS S, DEV LK, DICKERSON SH, FERONE R, HEATH LS, HUMPHREYS J, KNICK V, PENDERGAST W, SINGER S, SMITH GK, WATERS K, WILSON HR: Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res. (1993) 53:810-818. (Pubitemid 23077867)
29. FRY DW, ANDERSON LA, BORST M, GOLDMAN ID: Analy sis of the role of membrane transport in gut and Ehrlich tumor in vivo as factors in drug sensitivity and selectiv ity. Cancer Res. (1983) 43:1087-1092. (Pubitemid 13160027)
30. POSER RG, SIROTNAK FM, CHELLO PL: Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res. (1981) 41:4441-4446. (Pubitemid 12201355)
31. RUMBERGER BG, BARRUECO JR, SIROTNAK FM: Differing specificities for 4-amlnofolate analogs of folylpolyglu-tamyl synthetase from tumours and proliferative intestinal epithelium of the mouse 'with significance for selective antitumour action. Cancer Res. (1990) 50:4639-4643. (Pubitemid 20230406)
32. SIROTNAK FM, MCGRAW JI: Selective antitumour action of folate analogs. In: Folate Antagonists as Therapeutic Agents. SirotnakFM,BurchallJJ,Ensminger WD, Montgomery JA (Eds.), Academic Press, New York (1984) 2:43-95.
33. WHITEHEAD VM, ROSENBLATT DS, VUCHICH MJ et al: Accumulation of methotrexate and methotrexate poly-glutamate in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood (1990) 76:.44-49. (Pubitemid 20220789)
34. JONES TR, THORNTON TJ, FLINN A, JACKMAN AL, NEWELL DR, CALVERT AH: Quinazoline antifolates inhibiting thymidylate synthase: 2-desamlno derivatives with enhanced solubility and potency. J. Med. Chem. (1989) 32:847-852. (Pubitemid 19100198)
35. JACKMAN AL, TAYLOR GA, O'CONNOR BM, BISHOP JA, MORAN RG, CALVERT AH: Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8- dideazafolic acid and related compounds in murine (L1210) and human CW1L2) systems in vitro and in L1210 in vivo. Cancer Res. (1990) 50: 5212-5218. (Pubitemid 20302964)
36. HARRAP KR, JACKMAN AL, NEWELL DR, TAYLOR GA, HUGHES LR, CALVERT AH: Thymidylate synthase, a target for anticancer drug design. In: Advances in Enzyme Regulation. Weber G (Ed.), Pergamon Press, New York (1989) 29:161-179.
37. HUGHES LR, JACKMAN AL, OLDFIELD J, SMITH RC, BURROWS KD, MARSHAM PR, BISHOP JAM, JONES TR, O'CONNOR BM, CALVERT AH: Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted al-kyl, and aryl substituents in the C2 position. J. Med. Chem. (1990) 33:3060-3067. (Pubitemid 20349536)
38. JACKMAN AL, NEWELL DR, GIBSON W, JODRELL DI, TAYLOR GA, BISHOP JA, HUGHES LR, CALVERT AH: The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafollc acid (ICI 198583). Biochem. Pharmacol. 1991; 42:1885-1895.
39. MORAN RG, COLMAN PD, ROSOWSKY A, FORSCH RA, CHAN KK: Structural features or 4-amino folates required for substrate activity-with mammalian folylpoly-glutamate synthetase. Mol. Pharmacol. (1985) 27:156-166. (Pubitemid 15162399)
40. MORAN RG, COLMAN PD, JONES TR: Relative substrate activities of structurally related pterldine, quinazoline, and pyrimidlne analogs for mouse liver folylporygluta-mate synthetase. Mol. Pharmacol. (1990) 36:736-743. (Pubitemid 20008220)
41. JACKMAN AL, MARSHAM PR, MORAN RG, KIMBELL R, O'CONNOR BM, HUGHES LR, CALVERT AH: Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8- dideazafolates. Adv. Enz. Regul. (1991) 31:13-27.
42. JACKMAN AL, MARSHAM PR, THORNTON TJ, BISHOP JAM, O'CONNOR BM, HUGHES LR, CALVERT AH, JONES TR: Quinazoline antifolate thymidylate synthase inhibitors: 2'-fluoro-N10-propargyl-5,8-dideazafolic acid and derivatives with modifications in the C2 position. J. Med. Chem. (1990) 33:3067-3071. (Pubitemid 20349537)
43. MARSHAM PR, JACKMAN AL, OLDFIELD J, HUGHES LR, THORNTON TJ, BISSET GMF, O'CONNOR BM, BISHOP JAM, CALVERT AH: Quinazoline antifolate thymidylate synthase inhibitors: benzoyl ring modifications in the C2-methyl series. J. Med. Chem. (1990) 33:3072-3078. (Pubitemid 20349538)
44. MARSHAM PR, HUGHES LR, JACKMAN AL, HAYTER AJ, OLDFIELD J, WARDLEWORTH JM, BISHOP JA, O'CONNOR BM, CALVERT AH: Quinazoline antifolate thymidylate synthase Inhibitors: hetereocyclic benzoyl ring modifications. J. Med. Chem. (1991) 34:1594-1605.
45. SANGHANI PC, JACKMAN AL, EVANS VR, THORNTON T, HUGHES L, CALVERT AH, MORAN RG: A strategy for the design of membrane-permeable folylpolyglutamate synthetase inhibitors: 'bay region'-substltuted 2-de-samino-2-methyl-5,8- dldeazafolate analogues. Mol. Pharmacol. (1994) 45:341-351.
46. JACKMAN AL, KIMBELL R, BROWN M, BRUNTON L, BOYLE FT: Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Anti-Cancer Drug Design (1995) 10:555-572.
47. JACKMAN AL, TAYLOR GA, GIBSON W, KIMBELL R, BROWN M, CALVERT AH, JUDSON IR, HUGHES LR: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. (1991) 51:5579-5586.
48. JACKMAN AL, GIBSON W, BROWN M, KIMBELL R, BOYLE FT: The role of the reduced-folate carrier and metabo lism to intracellular polyglutamates for the activity of ICID1694. In: Proc. of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumours.-Laboratory and Clinical Correlation. Rustum Y (Ed.), Plenum Press, New York. Adv. Exp. Med. Biol. (1993) 339:265-276. (Pubitemid 24073371)
49. WARD WHJ, KIMBELL R, JACKMAN AL: Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem. Pharmacol. (1992) 43:2029-2031.
50. JACKMAN AL, KELLAND LR, KIMBELL R, BROWN M, GIB-SON W, AHERNE GW, HARDCASTLE A, BOYLE FT: Mecha nisms of acquired resistance to the quinazoline thymidylate synthase inhibitor, ZD1694 (Tomudex) in one mouse and three human cell lines. Br. J. Cancer (1995) 71:914-924.
51. JACKMAN AL, FARRUGIA DC, GIBSON W, KIMBELL R, HARRAP KR, STEPHENS TC, AZAB M, BOYLE FT: ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer (1995) 31A: 1277-1282.
52. GIBSON W, BISSET GMF, MARSHAM PR, KELLAND LR, JUDSON IR, JACKMAN AL: The measurement of polyglu-tamate metabolites of the thymidylate synthase inhibi tor, ICI D1694, in mouse and human cultured cells. Biochem. Pharmacol. (1993) 45:863-869. (Pubitemid 23071436)
53. LI W-W, TONG WP, BERTINO JR: Antitumour activity of antifolate inhibitors of thymidylate and purine synthe sis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate. Clin. CancerRes. (1995) 1:631-636.
54. STEPHENS TC, SMITH MN, WATERMAN SE, MCCLOSKEY ML, JACKMAN AL, BOYLE FT: Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antltumour efficacy evaluation of novel thymidine synthase inhibitors. In: Chemistry and Biology of Pteridines and Folates. Advances in Experimental Medicine and Biology. Ayling JE, Nair MG, Baugh CM (Eds.), Plenum Press, New York (1993) 338:589-592. (Pubitemid 23340656)
55. SMITH SG, LEHMAN NL, MORAN RG: Cytotoxicity of antlfolate inhibitors of thymidylate and purine synthesis to WiDR colonic carcinoma cells. Cancer Res. (1993) 53:5697-5706. (Pubitemid 23360274)
56. AHERNEW,HARDCASTLEA,KELLANDL,JACKMANA:The Measurement of deoxynucleotide (dNTP) pools by radioimmunoassay. In: Purine and Pyrimidine Metabolism in Man. Sahota A, Taylor MW (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1995) 370:801-804.
57. JACKMAN AL, TAYLOR GA, CALVERT AH, HARRAP KR: Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazolinebased thymidylate synthetase inhibitor, CB 3717. Biochem. Pharmacol. (1984) 33:3269-3275. (Pubitemid 14023263)
58. CLARKE SJ, JACKMAN AL, JUDSON IR: The toxicity of ICI D1694 In man and mouse. In: Chemistry and Biology of Pteridines and Folates. Ayling JE, NairMG, Baugh CM (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1993) 338:601-604. (Pubitemid 23340659)
59. JODRELL DI, NEWELL DR, CALVETE JA, STEPHENS TC, CALVERT AH: Pharmacokinetic and toxicity studies with the novel quinazoline thymidylate synthase inhibitor, D1694. Proc. Amer. Assoc. Cancer Res. (1990) 31:341.
60. JODRELL DI, NEWELL DR, MORGAN SE, CLINTON S, BEN-STED JPM, HUGHES LR, CALVERT AH: The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. Br. J. Cancer(199D 64:833-838.
61. CLARKE SJ, HANWELL J, DE BOER M, PLANTING A, VER-WEIJ J, WALKER M, SMITH R, JACKMAN AL, HUGHES LR, HARRAP KR, KENNEALEY GT, JUDSON IR: Phase I trial of ZD1694 (Tomudex), a new folate based, thymidylate synthase inhibitor. J. Clin. Oncol. (1996) 14:1496-1503.
62. SORENSON JM, JORDAN E, GREM JL et al.: Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann. Oncol. (1994) 5(Suppl. 5):132.
63. CUNNINGHAM D, ZALCBERG J, SMITH IE et al: Tomudex: a novel thymidylate synthase inhibitor with clinical antltumour activity in a range of solid tumours. Ann Oncol. (1994) 5(Suppl. 8):179.
64. ZALCBERG JR, CUNNINGHAM D, VAN CUSTEM E, FRAN-COIS E, SCHORNAGEL, ADENIS A, GREEN M, IVESON A, AZAB M, SEYMOUR L: A novel thymidylate synthetase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Oncol. (1996) 14:716-721. (Pubitemid 26085514)
65. CUNNINGHAM D, ZALCBERG JR, RATH U et al: Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur. J. Cancer{1995) 31A:1945-1954. (Pubitemid 26024292)
66. SEITZ JF, CUNNINGHAM D, RATH U, OLVER IN, VAN CUSTEM E, KERR D, SVENSSON C, PEREZ MANGA G, HARPER P, ZALCBERG J, LOWERY K, AZAB M: Final results and survival data of a large randomised trial of Tomudex in advanced colorectal cancer confirm comparable efficacy to 5-fluorouracll plus leucovorln (5FU+LV). Proc. ASCO (1996).
67. MOERTEL CG, FLEMING TR, MACDONALD JS et al.: Fluorouracil plus Levimisole as effective adjuvant therapy after resection of stage m colon carcinoma: a final report. Ann. Inter. Med. (1995) 122:321-326.
68. LABIANCA R, MARSONI S, PANCERA G, TORRI V, ZANI-BONI A, ERIiCHMAN C, PATERJ, SHEPERD L, ZEE B, SEITZ JF, MILAN C, PIGNONJP: Efficacy of adjuvant fluorouracil and folinic acid In colon cancer. Lancet (1995) 345:939-944.
69. TAYLOR EC, KUHNT D: A dideazatetrahydrofolate ana-logue lacking a chiral center at C-6, N-[4-[2-(2-amlno-3,4-dihydro-4-oxo-7i/-pyrrolo[2,3-,3- flpyrimidin-5-yl) ethyl] benzoyl]-L-glutamlc acid, Is an inhibitor of thymidylate synthase, J. Med. Chem., 1992, 35, 4450-4454.
70. SHIH C, GOSSETT L, GATES S, MACKELLAR W, MENDEL-SOHN L, SOOSE D, PATEL V, KOHLER W, RATNAM M: LY231514 and its polyglutamates exhibit potent Inhibi tion against both human dihydrofolate reductase and thymidylate synthase: multiple folate enzymes inhibi tion. Ann. Oncol. (1996) 7(Suppl. 1):85.
71. SCHULTZ R, ANDIS S, CHEN V, MENDELSOHN L, PATEL V, SHIH C, HOUGHTON J: Comparative antltumour activity of the multitargeted antlfolate LY231514 and the thymidylate synthase Inhibitor ZD1694. Ann. Oncol. (1996)7(Suppl. 1):85.
72. CHEN VJ, BEWLEYJR, GOSSETT L, SHIH C, SOOSE D, PATEL V, GATES S, MACKELLAR W, HABECK LL, SHACKELFORD KA, MENDELSOHN L, KOHLER W, RATNAM M: Activity of LY231514 against several enzymes in the folate-depend-ent pathways. Proc. Am. Assoc. Cancer Res. (1996) 37:381.
73. GRINDEY GB, SHIH C, BARNETT CJ, PEARCE HL, ENGEL-HARDT JA, TODD GC, RINZEL SM, WORZALLAJF, GOSSELL LS, EVERSON TP, WILSON TM, KOBIERSKI ME, WINTER MA, BEWLEY JR, KUHNT D, TAYLOR EC, MORAN RG: LY231514, a novel pyrrolpyrimidine antlfolate that inhibits thymidylate synthase. Proc. Am. Assoc. Cancer Res. (1992) 33:411.
74. RINALDI DA, BURRIS HA, DORR FA, WOODWORTH JR, KUHN JG, ECKARDT JR, RODRIGUEZ G, CORSO SW, FIELDS SM, LANGLEY C, CLARK G, FARIES D, LU P, VON HOFF DD: Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassment method for dose escalation. J. Clin. Oncol. (1995) 13:2842-2850.
75. VASEY PA, CALVERT AH, KAYE SB, CASSIDY J: Clinical phase I study of LY231514 (an inhibitor of thymidylate synthase) using a daily x5 q 21 schedule. Ann. Oncol. (1994) 5:(Suppl. 5)131.
76. MCDONALD AC, VASEYPA, WALLING J, LINDB MJ, BAILEY NP, SIDDIQUIB N, TWELVES C, CASSIDY J, KAYE SB: Clinical phase I study of LY231514, a multitargeted antlfolate, administered by daily x 5 q 21 schedule. Ann. Oncol. (1996) 7(Suppl. 1):5.
77. RINALDI D, BURRIS HA, DORR G et al: A phase I evalu-ation of LY231514, a novel multi-targeted antlfolate administered every 21 days. Proc. ASCO (1996) 15:489
78. PENDAGAST W, DICKERSON SH, JOHNSON JV, DEV IK, FERONE R, DUCH DS, SMITH GK: Benzoquinazoline in hibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some sulfonamidobenzoyl-glutamate and related derivatives. J. Med. Chem. (1993) 36:3464-3471. (Pubitemid 23335713)
79. WEICHSEL A, MONTFORT WR: Ligand-induced distortion of an active site in thymidylate synthase upon binding anticancer drug 1843U89. Nature Struct. Biol. (1995) 2:1095.
80. DEV IK, DALLAS WS, FERONE R etal. Mode of binding of folate analogs to thymidylate synthase. J. Biol. Chem. (1994) 269:1873-1882.
81. MCGUIRE JJ, HEITZMAN KJ, HAILE WH, RUSSELL CA, MCCLOSKEY DE, PIPER JR: Studies on the cross resistance of folylpolyglutamate synthetase-deficient, methotr-exate-reslstant CCRF-CEM human leukemia sublines. In: Chemistry and Biology of Pteridines and Folates. Ayling JE, Nair MG, Baugh CM (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1993) 338:667-670. (Pubitemid 23340674)
82. SMITH GK, AMYX H, BOYTOS CM, DUCH DS, FERONE R, WILSON HR: Enhanced antitumour activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res. (1996) 55:6117-6125.
83. WILSON HR, HEATH LS, KNICK VC, KOSSALKA GW, FERONE R: In vivo antitumour activity of 1843U89 a new antifolate thymidylate synthase Inhibitor. Proc. Am. Assoc. Cancer Res. (1992) 33:407.
84. SIROTNAK FM, MOCCIO DM, YANG CH: Similar characteristics of folate analogue transport in vitro in contrast to dihydrofolate reductase levels in epithelial cells at different stages of maturation of mouse small intestine. CancerRes. (1894) 44:5204-5211.
85. BURRIS HA, SMETZER LA, RODRIGUEZ GI, RINALDI DA, LAMPKIN TA, BIGLEY JW, VON HOFF DD: A phase I study of the novel thymidylate synthase inhibitor 1843U89 with and without high dose oral folate. Proc. ASCO (1996).
86. BURRIS HA, KISOR DF, SMETZER LA, ECKARDT JR, RODRIGUEZ GI, RINALDI DA, LAMPKIN TA, BIGLEY JW, VON HOFF DD: A Phase I pharmacokinetic study of the thymydylate synthase inhibitor 1843U89 during a daily x5 bolus administration schedule. Proc. ASCO (1996).
87. FLEMING GF, SCHLILSKY RL: Antifolates: the next generation. Semin. Oncol. (1992) 19:707-719. (Pubitemid 23004847)
88. FRY DW, JACKSON RC: Biological and biochemical properties of new anticancer folate antagonists. Cancer Metastasis Rev (1987) 5:251-270.
89. MCGUIRE JJ, RUSSELL CA, BOLANOWSKA WE, FREITAG CM, JONES CS, KALMAN TI: Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the y-carboxyl group. CancerRes. (1990) 50:1726-1731. (Pubitemid 20098811)
90. MCGUIRE JJ, GRABER M, LICATO NJ, VINCENZ C, COWARD JK, NIMEC Z, GALTVAN J: Biochemical and growth inhibitory properties of the erythro and threo isomers of y-fluoromethotrexate, a methotexate analog defective in polyglutamation. CancerRes. (1989) 49:4517-4525. (Pubitemid 19208355)
91. GALIVAN J, INGLESE J, MCGUIRE J, NIMEC Z, COWARD JK: y- Fluoromethotrexate: synthesis and biological activity of a potent Inhibitor of dihydrofolate reductase with greatly diminished ability to form poly-y-glutamate. Proc. Natl Acad Sci. USA (1985) 82:2598.
92. ABRAHAM A, NAIR MG, MCGUIRE JJ, GALIVAN J, KISLIUK RL, VISHNUVAJJALA: Antitumour efficacy of classical non-polyghitamylatable antifolates that Inhibit dihydrofolate reductase. In: Chemistry and Biology of Pteridines and Folates. Ayling JE, Nair MG, Baugh CM (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1993) 338:663-666. (Pubitemid 23340673)
93. BOYLE FT, MATUS1AK ZS, HUGHES LR, SLATER AM, STEPHENS TC, SMITH MN, K1MBELL R, JACKMAN AL, Substltuted-2-dcsamlno-2-methyl-qulnazollnones. A series of novel antitumour agents. In: Chemistry and Biology of Pteridines and Folates. Ayling JE, Nair MG, Baugh CM (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1993) 338:585-588. (Pubitemid 23340655)
94. BAVETSIAS V, JACKMAN AL, KIMBELL R, GIBSON W, BOYLE FT, BISSET GMF: Quinazollne antifolate uiymidy late synthase inhibitors: y-linked L-D, D-D and D-L dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazfolic acid (ICI 198583). J. Med. Chem. (1995) 39:73-85.
95. MARSHAM PR, JACKMAN AL, BARKER AJ, BOYLE FT, PEGG SJ, WARDLEWORTH JM, KIMBELL R, OGONNOR BM, CALVERT AH, HUGHES LR: Quinazollne antifolate mymidy-late synthase Inhibitors: Replacement of glutamic add in the C2-methyl series. J.Med. Chem. (1995) 38:994-1004.
96. JACKMAN AL, KIMBELL R, BROWN M, BRUNTON L, HAR-RAP KR, WARDLEWORTH JM, BOYLE FT: The antitumour activity of ZD9331, a non-polyglutamatable quinazollne thymidylate synthase inhibitor. In: Purine and Pyrimid-ine Metabolism in Man VIII. Sahota A, Taylor M (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1995) 370:185-188.
97. BOYLE FT, WARDLEWORTH JM, HENNEQUIN LF, KIMBELL R, MARSHAM PR, STEPHENS TC, JACKMAN AL. ZD9331-Design of a novel non-polyglutamatable qulnazoline-based inhibitor of thymidylate synthase. Proc. Am. Assoc. CancerRes. (1994) 35:302.
98. JACKMAN AL, KIMBELL R, BROWN M, BRUNTON L, HAR-RAP KR, WARDLEWORTH JM, BOYLE FT: The antitumour activity of ZD9331, a non-polyglutamatable quinazollne thymidylate synthase inhibitor. In: Purine and Pyrimid-ineMetabolism in Man. Sahota A, Taylor MW (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1995) 370:185-188.
99. JACKMAN AL, BISSET GMF, JODRELL DI et al: y-Linked dipeptide analogues of 2-desamlno-2-methyl-N10-propargyl-5,8-dideazafolate as antitumour agents. In: Chemistry and Biology of Pteridines and Folates. Ayling JE, Nair MG, Baugh CM (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1993) 338:579-584. (Pubitemid 23340654)
100. JACKMAN AL KIMBELL R, BRUNTON L, AHERNE GW, WALTON M, KELLAND L: Activity of ZD1694 and ZD9331 in human colon and ovarian tumour lines. Proc. Am. Assoc. CancerRes. (1996) 37:382.
101. AHERNE W, HARDCASTLE A, KELLAND L, JACKMAN A: The Measurement of deoxynucleotide (dNTP) pools by radioimmunoassay. In; Purine and Pyrimidine Metabolism in Man. Sahota A, Taylor MW (Eds.), Plenum Press, New York. Adv. Exp. Med. Biol. (1995) 370:801-804.
102. STEPHENS TC, SMITH MN, MCCLOSKEY ML, WATERMAN SE, GWYNNE AJ, VALCACCIA BE, JACKMAN AL, WARDLE WORTH JM, BOYLE, FT: ZD9331, a novel non-pob/ghita-mated thymidylate synthase inhibitor: in vivo antitumour efficacy and toxicity to normal murine tissues. Proc. Am. Assoc. CancerRes. (1994) 35:305.
103. AHERNE GW, WARD E, DOBINSON D, HARDCASTLE A, JACKMAN AL: Pharmacokinetics of a bolus Injection of ZD9331, a non-polyglutamated thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res. (1996) 37:382.
104. MCNAMARA DJ, BERMAN EM, FRY DW, WERBEL LM: Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines. J. Med. Chem. (1990) 33:2045-2051. (Pubitemid 20229003)
105. APPELT K, BACQUET RJ, BARTLETT CA et al.: Design of enzyme inhibitors using iterative protein crystal-lographic analysis. J. Med. Chem. (1991) 34:1925-1934.
106. WEBBER SE, BLECKMAN TM, ATTARD J et al: Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J. Med. Chem. (1993) 36:733-746. (Pubitemid 23105727)
107. VARNEY MD, MARZONI GP, PALMER CL et al: Crystal-structure-based design and synthesis of benz[cd] indole-containing Inhibitors of thymidylate synthase, J. Med. Chem., 1992, 35, 663-676.
108. WEBBER S, BARTLETT CA, BORITZKI TJ, HILLIARD JA, HOWLAND EF, JOHNSTON AL, KOSA M, MARGOSIAK SA, MORSE CA, SHETTY BV: AG337, a novel lipophilc thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother. Pharmacol. (1996) 37:509-517. (Pubitemid 26080147)
109. CALVETE JA, BALMANNO K, TAYLOR GA, RAFI I, NEWELL DR, LIND MJ, CALVERT AH: Preclinical and clinical stud ies of prolonged administration of the novel thymidy late synthase inhibitor, AG337. Proc. Am. Assoc. Cancer Res. (1994) 35:306.
110. RAFI I, TAYLOR GA, CALVETE JA, BODDY AV, BALMANNO K, BAILEY N, LIND M, CALVERT AH, WEBBER S, JACKSON RC, JOHNSTON A, CLENDENINN N, NEWELL DR: Clinical pharmacokinetic and pharmacodynamic studies-with die nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4- pyridylthio)-quinazolone dlhydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clin. Cancer Res. (1995) 1:1275-1284.
111. RAFI I, BODDY AV, TAYLOR GA, CALVETE JA, GRIFFIN M, CALVERT AH, LIND M, BAILEY N, JOHNSTON A, CLENDEN INN N, NEWELL DR: Pharmacokinetic and pharmacody namic studies of the non-classical thymidylate synthase inhibitor AG337 given as a 5 day iv infusion. Ann. Oncol. (1996) 7(Suppl. 1):86.
112. RAFI I, BODDY AV, TAYLOR GA et al: Pharmacokinetic and pharmacodynamic studies of the non-classical thymidylate synthase inhibitor AG337 given as a 5 day iv infusion. Proc. Am. Assoc. Cancer Res. (1996) 37:177.
113. CLENDENNIN NJ, JOHNSTON A et al: Phase H trials of Thymltaq™ (AG337) in six solid tumor diseases. Ann. Oncol. (1996) 7(Suppl. 1):86.
114. CLENDENNIN NJ, COLLIER MA, JOHNSTON AL, LOH KK, COHN A, KELLY K, GLODE LM, STUART KE, BELANI CP: Thymltaq™ (AG337): a novel thymidylate synthase inhibitor with clinical activity in solid tumours. Proc. Am. Assoc. Cancer Res. (1996) 37:171.
115. CREAVEN PJ, PENDYALA L, MEROPOL NJ, WU EY, CLENDENINN NJ: Phase I and pharmacokinetic study of 3,4-dihydro-2-amlno-6-mediyl-4-oxo-5)-quinazoline dlhydrochloride (THYMTTAQ®, AG337). Ann. Oncol. (1996) 7(Suppl. 1):85.
116. RAH I, BODDY AV, TAYLOR GA, CALVETE JA, BAILEY NB, LIND MJ, NEWELL DR, CALVERT AH: A Phase I clinical study of the novel antifolate AG337 given by 5 day oral administration. Ann. Oncol. (1996) 7(Suppl. 1):86.
117. JODRELL D, BOWMAN A, RYE R, SMYTH JF, BODDY A, RAFI I, TAYLOR G, JOHNSTON A, CLENDENINN NJ: A clinical phase I, pharmacokinetic and pharmacodynamic study of the lipophilic thymidylate synthase inhibitor Thymltaq'™ (AG337) administered by 10 day oral administration. Ann. Oncol. (1996) 7(Suppl. 1):86.
118. JODRELL D, BOWMAN A, RYE R, SMYTH JF, BODDY A, RAFI I, TAYLOR G, JOHNSTON A, CLENDENINN NJ: A Phase I, pharmacokinetic/pharmacodynamic study of the lipophilic thymidylate synthase inhibitor Thymltaq™ (AG337) administered orally, 6 hourly for 10 days. Proc. Am. Assoc. Cancer Res. (1996) 37:184.
119. WEBBER S, SHETTY B, JOHNSTON A et al: In vitro properties and antitumour activity of AG-331, a novel lipophilic thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res. (1992) 33:413.
120. O'CONNOR BM, WEBBER S, JACKSON RC, GALIVAN J, RHEE MS: Biological activity of a novel rationally designed lipophilic thymidylate synthase Inhibitor. Cancer Chemother. Pharmacol. (1994) 34:225-229. (Pubitemid 24178513)
121. CLENDENNINN NJ, PETERKIN JJ, WEBBER S et al: AG331, a 'non-classical' lipophilic thymidylate synthase inhibitor for the treatment of solid tumours. Ann. Oncol. (1994) 5(Suppl. 4):133.
122. PARIMOO D, MUGGIA F, LEICHMAN CG etal: Phase I and pharmacokinetic study of AG331, a non-classical thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res. (1996) 37:184.
123. GIANTONIO B, OIAN M, GALLO J et al: Phase I trial of AG331 as a 5-day continuous infusion. Proc. ASC00995) 14:480.